Publikationer från Malmö universitet
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
Gidvall, Sanna
Publikationer (2 of 2) Visa alla publikationer
Riaz, A., Gidvall, S., Prgomet, Z., Hernandez, A. R., Ruzgas, T., Nilsson, E. J., . . . Valetti, S. (2023). Three-Dimensional Oral Mucosal Equivalents as Models for Transmucosal Drug Permeation Studies. Pharmaceutics, 15(5), 1513-1513
Öppna denna publikation i ny flik eller fönster >>Three-Dimensional Oral Mucosal Equivalents as Models for Transmucosal Drug Permeation Studies
Visa övriga...
2023 (Engelska)Ingår i: Pharmaceutics, ISSN 1999-4923, E-ISSN 1999-4923, Vol. 15, nr 5, s. 1513-1513Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Oral transmucosal administration, where drugs are absorbed directly through the non-keratinized, lining mucosa of the mouth, represents a solution to drug delivery with several advantages. Oral mucosal equivalents (OME) developed as 3D in vitro models are of great interest since they express the correct cell differentiation and tissue architecture, simulating the in vivo conditions better than monolayer cultures or animal tissues. The aim of this work was to develop OME to be used as a membrane for drug permeation studies. We developed both full-thickness (i.e., connective plus epithelial tissue) and split-thickness (i.e., only epithelial tissue) OME using non-tumor-derived human keratinocytes OKF6 TERT-2 obtained from the floor of the mouth. All the OME developed here presented similar transepithelial electrical resistance (TEER) values, comparable to the commercial EpiOral™. Using eletriptan hydrobromide as a model drug, we found that the full-thickness OME had similar drug flux to EpiOral™ (28.8 vs. 29.6 µg/cm2/h), suggesting that the model had the same permeation barrier properties. Furthermore, full-thickness OME showed an increase in ceramide content together with a decrease in phospholipids in comparison to the monolayer culture, indicating that lipid differentiation occurred due to the tissue-engineering protocols. The split-thickness mucosal model resulted in 4–5 cell layers with basal cells still undergoing mitosis. The optimum period at the air–liquid interface for this model was twenty-one days; after longer times, signs of apoptosis appeared. Following the 3R principles, we found that the addition of Ca2+, retinoic acid, linoleic acid, epidermal growth factor and bovine pituitary extract was important but not sufficient to fully replace the fetal bovine serum. Finally, the OME models presented here offer a longer shelf-life than the pre-existing models, which paves the way for the further investigation of broader pharmaceutical applications (i.e., long-term drug exposure, effect on the keratinocytes’ differentiation and inflammatory conditions, etc.).

Ort, förlag, år, upplaga, sidor
MDPI, 2023
Nyckelord
oral transmucosal delivery, oral mucosal equivalents, drug permeation, 3R principles, 3D in vitro models
Nationell ämneskategori
Farmaceutiska vetenskaper
Identifikatorer
urn:nbn:se:mau:diva-61046 (URN)10.3390/pharmaceutics15051513 (DOI)000997495400001 ()37242755 (PubMedID)2-s2.0-85160448981 (Scopus ID)
Forskningsfinansiär
Crafoordska stiftelsen, 20210937KK-stiftelsen, 20190010
Tillgänglig från: 2023-06-19 Skapad: 2023-06-19 Senast uppdaterad: 2023-08-15Bibliografiskt granskad
Gidvall, S., Björklund, S., Feiler, A., Dahlström, B., Rönn, R., Engblom, J. & Valetti, S. (2021). A novel versatile flow-donor chamber as biorelevant ex-vivo test assessing oral mucoadhesive formulations. European Journal of Pharmaceutical Sciences, 166, Article ID 105983.
Öppna denna publikation i ny flik eller fönster >>A novel versatile flow-donor chamber as biorelevant ex-vivo test assessing oral mucoadhesive formulations
Visa övriga...
2021 (Engelska)Ingår i: European Journal of Pharmaceutical Sciences, ISSN 0928-0987, E-ISSN 1879-0720, Vol. 166, artikel-id 105983Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Oral transmucosal drug delivery is a non-invasive administration route for rapid therapeutic onset and greater bioavailability avoiding the first-pass metabolism. Mucoadhesive formulations are advantageous as they may retain the drug at the administration site. Proper equipment to assess mucoadhesive properties and corresponding drug absorption is fundamental for the development of novel drug delivery systems. Here we developed a new flow-through donor chamber for well-established diffusion cells, and we tested the effects on drug and formulation retention in situ of adding mucoadhesive polymers or mesoporous silica particles to a reference formulation. Mesoporous silica particles are of particular interest as they may be used to encapsulate and retain drug molecules. Compared to other ex-vivo methods described in literature for assessing mucoadhesive performance and transmucosal drug delivery, this new donor chamber provides several advantages: i) it reflects physiological conditions better as a realistic saliva flow can be provided over the administration site, ii) it is versatile since it can be mounted on any kind of vertical diffusion cell allowing simultaneous detection of drug retention at the administration site and drug permeation through the tissue, and iii) it enables optical quantification of formulations residence time aided by image processing. This new flow-through donor diffusion cell set-up proved sensitive to differentiate a reference formulation from one where 20 %(w/w) Carbomer was added (to further improve the mucoadhesive properties), with respect to both drug and formulation residence times. We also found that mesoporous silica particles, investigated as particles only and mixed together with the reference formulation, gave very similar drug and formulation retention to what we observed with the mucoadhesive Carbomer. However, after some time (>30 min) it became obvious that the tablet excipients in the reference formulation promote particle retention on the mucosa. This work provides a new simple and versatile biorelevant test for the evaluation of oral mucoadhesive formulations and paves the way for further studies on mesoporous silica particles as valuable excipients for enhancing oral mucoadhesion.

Ort, förlag, år, upplaga, sidor
Elsevier, 2021
Nyckelord
Ex-vivo release-permeation systems, Flow through diffusion cells, Intraoral drug delivery, Mesoporous silica particles, Mucoadhesion, Oral transmucosal delivery
Nationell ämneskategori
Farmaceutiska vetenskaper
Identifikatorer
urn:nbn:se:mau:diva-45899 (URN)10.1016/j.ejps.2021.105983 (DOI)000704269600004 ()34461276 (PubMedID)2-s2.0-85114373054 (Scopus ID)
Tillgänglig från: 2021-09-15 Skapad: 2021-09-15 Senast uppdaterad: 2024-02-05Bibliografiskt granskad
Organisationer

Sök vidare i DiVA

Visa alla publikationer